An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer
Clinical trial NCT06532344 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06532344
- Sponsor
- Ono Pharmaceutical Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-30
- Primary completion
- 2026-12-31
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.